Farms.com Home   News

MS Technologies And Bayer Receive Chinese Approval For Balance GT Soybeans

MS Technologies and Bayer have received import approval from China for Balance GT soybeans. The new Balance GT Soybean Performance System will combine industry-leading genetics with a double herbicide-tolerant trait that will confer tolerance to glyphosate and isoxaflutole, the active ingredient in the new Balance Bean herbicide. The Balance GT Soybean Performance System will benefit soybean growers by providing high-yielding genetics and protection against a variety of broadleaf weeds and grasses. 
 
This is a significant milestone in the Balance GT approval process, moving the new soybean trait closer to commercialization for our soybean producers. Balance GT has already received approvals from critical countries, including Argentina, Brazil, Canada, the European Union and the United States. Balance Bean herbicide is pending EPA registration. The Balance GT Soybean Performance System will not be commercially available until the system has received all required regulatory approvals. 
 
"We are thrilled to have received approval from China - a key country in the process of bringing this technology to the market. Balance GT will truly improve the future of farming through its high-yielding genetics and control over glyphosate-resistant weeds," said Joseph Merschman, president of MS Technologies. 
 
MS Technologies and Bayer have been collaborating for more than a decade to commercialize new herbicide-tolerant technologies for soybeans, starting with the LibertyLink system in 2009. Balance GT will mark the second collaboration for the two companies and will provide a strong alternative to current weed management options. 
Click here to see more...

Trending Video

Market to Market

Video: Market to Market

Warmer temperatures take hold across much of the country. A new wave of farmers joins widespread European protests. Having that difficult talk with your elders - farm transitions. And, commodity market analysis with Ted Seifried.